SCHEMBL21091348

SCHEMBL21091348

CCC(C)C(C)c1cccc(-c2ccn(C)n2)c1C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.36
▸ MPO P05164 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ PDE1A P54750 8/20 0.34
▸ PDE1B Q01064 8/20 0.34
▸ PDE1C Q14123 8/20 0.34
▸ JAK2 O60674 2/20 0.34
▸ JAK1 P23458 2/20 0.34
▸ TYK2 P29597 2/20 0.34
▸ JAK3 P52333 2/20 0.34
▸ ADRA1D P25100 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ ADRA1B P35368 1/20 0.33
▸ JMJD6 Q6NYC1 2/20 0.33
▸ GRM5 P41594 1/20 0.32
▸ GRM1 Q13255 1/20 0.32
▸ CYP19A1 P11511 1/20 0.32
▸ KEAP1 Q14145 1/20 0.31
▸ CASP6 P55212 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21091006 0.83 KMT2A (0.36) KMT2AMPOCYP3A4PDE1APDE1B
SCHEMBL18367714 0.82 KMT2A (0.42) KMT2AMPOCYP3A4PDE1APDE1B
SCHEMBL19589424 0.73 MPO (0.46) KMT2AMPOCYP3A4JAK2JAK1
SCHEMBL18713633 0.73 KMT2A (0.46) KMT2APDE1APDE1BPDE1CJAK2
SCHEMBL18378772 0.72 KMT2A (0.47) KMT2AMPOCYP3A4JAK2JAK1
SCHEMBL6312157 0.69 KMT2A (0.44) KMT2AMPOCYP3A4ADRA1DADRA1A
SCHEMBL17194964 0.67 KMT2A (0.42) KMT2AMPOCYP3A4ADRA1DADRA1A
SCHEMBL5754567 0.67 APLNR (0.45) KMT2AMPOCYP3A4JAK2GRM5
SCHEMBL18415121 0.67 TYK2 (0.40) KMT2AJAK1TYK2GRM5GRM1
SCHEMBL29767299 0.65 KMT2A (0.55) KMT2ACYP3A4JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495358-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES Bristol-Myers Squibb Company (US) 2019-06-12 — — EP disclosed
Send feedback